한글목차

유전자 치료 세계 시장 규모는 2024년 65억 4,000만 달러로 평가되었고, 예측 기간 동안 9.53%의 연평균 복합 성장률(CAGR)로 2030년에는 112억 9,000만 달러에 달할 것으로 예상됩니다.

유전자 치료는 질병의 원인이 되는 유전자 조합의 결손이나 결함을 변경, 대체, 보완하여 질병을 치료하는 것으로 설명됩니다. 유전자 치료는 퇴행성 질환과의 싸움에서 가장 바람직한 연구 목표 중 하나가 되었습니다. 유전자 치료의 필요성은 전 세계적으로 암 및 기타 만성 질환 증가로 인해 증가하고 있습니다. 유전자 치료의 발전은 향후 몇 년동안 승인될 것으로 예상되며, 이는 예측 기간 동안 유전자 치료 시장의 성장에 기여할 것으로 예상됩니다. 유전자 치료는 유전 정보를 변경하여 질병을 치료하기 위해 고안된 것으로, 기능 장애가 있는 유전자를 비활성화하거나 질병을 유발하는 유전자를 건강한 유전자 사본으로 대체하는 등 유전 정보를 변경하여 질병을 치료하는 것입니다. 유전자 치료는 다양한 질환의 치료에 활용되고 있으며, 그 효과가 입증되고 있습니다. 이 치료법은 당뇨병, 암, 심장병, 에이즈 등의 질병을 치료할 수 있습니다.

강력한 유전자 치료제 파이프라인이 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다. 연구자들은 유전자 치료제를 임상 현장에서 보다 쉽게 사용할 수 있도록 적극적으로 노력하고 있습니다. 많은 대학과 연구기관들이 다양한 유전자 치료 제품을 개발하고 있으며, 이는 향후 몇 년동안 수익 창출에 크게 기여할 것으로 예상됩니다. FDA의 첫 유전자치료제 승인 이후 2017년부터 2018년까지 유전자치료제 임상시험 건수는 눈에 띄게 증가하였습니다. 미국 유전자 및 세포치료학회(ASGCT)에 따르면, CAR T 세포치료제 및 기타 유전자 변형 세포치료제를 포함한 약 1,986개의 유전자치료제가 현재 개발 중으로 시장 확대가 더욱 가속화되고 있습니다.

주요 시장 성장 촉진요인

유전자 연구의 발전

주요 시장 이슈

기술적 복잡성

주요 시장 동향

치료 대상 확대

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 임상시험 분석

제4장 1 진행중 임상시험

제4장 완료한 임상시험 2건

제4장 중지된 임상시험 3건

제4장 4개발 단계별 파이프라인 내역

제4장 5 파이프라인 현황별 내역

제4장 6 파이프라인 내역(연구 유형별)

제4장 7지역별 파이프라인 내역

제4장 8개 임상시험 히트맵

제5장 고객의 소리

제6장 세계의 유전자 치료 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 벡터 유형별(바이러스 벡터, 비바이러스 벡터)
  • 투여 방법별(체내, 체외)
  • 적응증별(희귀질환, 암, 신경질환, 기타)
  • 지역별(북미, 유럽, 아시아태평양, 남미, 중동 및 아프리카)
  • 기업별(2024년)
• 시장 맵
• 벡터 유형별
• 배송 방법별
• 적응증별
• 지역별

제7장 북미의 유전자 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제8장 유럽의 유전자 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제9장 아시아태평양의 유전자 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제10장 남미의 유전자 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제11장 중동 및 아프리카의 유전자 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제12장 시장 역학

• 성장 촉진요인
• 과제

제13장 시장 동향과 발전

• 최근 동향
• 인수합병(M&A)
• 제품 출시

제14장 세계의 유전자 치료 시장 : SWOT 분석

제15장 자금조달 분석

제16장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제17장 경쟁 구도

• REGENXBIO Inc.
• Oxford Biomedica PLC.
• Voyager Therapeutics Inc.
• Human Stem Cells Institute
• Dimension Therapeutics, Inc.
• Bristol-Myers Squibb Company
• Sanofi
• F. Hoffmann-La Roche ltd.
• bluebird bio, Inc.
• Novartis AG
• Uniqure N.V.

제16장 전략적 제안

제17장 리서치사에 대해 & 면책사항

영문목차

Global Gene Therapy Market was valued at USD 6.54 Billion in 2024 and is expected to reach USD 11.29 Billion by 2030 with a CAGR of 9.53% during the forecast period. The gene therapy is described as the treatment of an illness by changing, replacing, or supplementing a missing or defective genetic combination that is responsible for the disease. The gene therapy has become one of the most desirable research goals in the fight against degenerative illnesses. The need for gene therapy is being driven by an increase in the number of cases of cancer and other chronic diseases all across the world. The advancements in gene therapies are projected to be approved in the upcoming years, contributing to the gene therapy market's growth during the forecast period. The gene therapies are designed to treat diseases by altering genetic information, such as inactivating malfunctioning genes or replacing a disease-causing gene with a healthy copy of gene. The gene therapy is being utilized to treat a variety of disorders and has demonstrated to be effective. This form of treatment can cure diseases such as diabetes, cancer, heart disease, and AIDS.

The strong pipeline of gene therapy products is anticipated to drive market growth over the forecast period. Researchers are actively working to make gene therapy more accessible in clinical settings. Numerous universities and research institutes are developing a diverse range of gene therapy products, which is expected to contribute significantly to revenue generation in the coming years. The number of clinical trials for gene therapy saw a notable increase between 2017 and 2018, following the FDA's approval of the first gene therapy. According to the American Society of Gene & Cell Therapy (ASGCT), approximately 1,986 gene therapy products, including CAR T-cell therapies and other genetically modified cell treatments, are currently in development, further accelerating market expansion.

Key Market Drivers

Advancements in Genetic Research

The increasing understanding of the genetic basis of diseases has enabled scientists to identify specific genes responsible for various disorders. This knowledge is crucial for designing targeted gene therapies that can correct or replace defective genes, addressing the root cause of diseases. Genetic research has identified specific genetic mutations or abnormalities that contribute to various diseases, such as inherited genetic disorders and certain types of cancer. This has provided gene therapists with clear therapeutic targets, allowing them to develop more precise and effective treatments. Advancements in gene editing technologies, such as CRISPR-Cas9, TALENs, and zinc finger nucleases, have revolutionized gene therapy. These techniques enable scientists to accurately and efficiently edit or modify genes, opening up new possibilities for treating genetic disorders. Genetic research has paved the way for personalized medicine, where treatments are tailored to an individual's genetic makeup. This approach enhances the effectiveness of gene therapies by considering genetic variations that might affect treatment outcomes, leading to better patient responses and reduced adverse effects. Genetic research has facilitated the development of advanced delivery systems that help target specific tissues or cells with greater precision. This has improved the efficiency of gene therapy treatments, minimized off-target effects and enhancing therapeutic outcomes. The promising outcomes of genetic research have attracted substantial investment in the gene therapy sector. As the potential of gene therapies becomes more apparent, investors are more willing to fund research and development, driving innovation and market growth. For example, in December 2023, the U.S. FDA approved a gene therapy for sickle cell disease, marking the first-ever gene therapy based on CRISPR gene editing. Such groundbreaking advancements and product launches are expected to drive market growth over the forecast period.

Key Market Challenges

Technical Complexity

Developing effective gene therapies requires a deep understanding of genetics, molecular biology, and complex cellular processes. The technical complexity of designing therapies that accurately target and modify specific genes can lead to prolonged research and development timelines. Getting therapeutic genes into target cells poses a significant challenge. Developing efficient and safe delivery systems, such as viral vectors or nanoparticles, requires extensive optimization and testing. Technical difficulties in achieving precise and controlled delivery can affect the success of gene therapies. The interactions between modified genes and the host organism can sometimes lead to unintended consequences. Technical complexities can make it difficult to predict the outcomes of gene therapies accurately, leading to safety concerns and regulatory challenges. Regulatory agencies require a high level of safety and efficacy data for gene therapy products due to their complexity and potential risks. Navigating the regulatory pathway for gene therapies can be challenging and time-consuming, hindering market growth. Manufacturing gene therapy products in a consistent and scalable manner is challenging due to the complexity of biological processes involved. Ensuring the quality, safety, and stability of gene therapies at a commercial scale can be technically demanding and expensive.

Key Market Trends

Expanding Therapeutic Targets

Identifying new therapeutic targets means gene therapy can be applied to a wider range of medical conditions beyond traditional monogenic disorders. This diversity includes complex diseases like cancer, cardiovascular diseases, neurodegenerative disorders, and rare diseases, expanding the addressable patient population. The availability of gene therapies for multiple therapeutic targets attracts a larger patient base, driving market growth by increasing the potential customer pool and commercial opportunities. The discovery of new therapeutic targets stimulates research and development efforts by both established pharmaceutical companies and smaller biotechnology firms. This influx of investment fuels innovation and accelerates the development of gene therapies for various indications. Expanding therapeutic targets leads to a more diverse portfolio of clinical trials. This diversity enhances the clinical trial landscape, allowing researchers to explore different patient populations, endpoints, and treatment approaches, ultimately advancing the field. As gene therapies target a wider array of diseases, regulatory agencies may provide specialized pathways or guidelines for specific indications. This attention can expedite regulatory approval processes and facilitate market entry. The availability of gene therapies for more common and relatable diseases can increase public awareness and acceptance of the technology. Positive outcomes in well-known conditions can build trust and reduce skepticism. Expanding therapeutic targets can lead to collaborations between academic researchers, industry partners, and patient advocacy groups. Collaborations strengthen expertise, resources, and support networks, fostering innovation and growth. The potential for gene therapies to target various indications attracts diverse investors interested in contributing to the development of treatments for specific diseases, fostering a competitive market landscape.

Key Market Players

• REGENXBIO Inc.
• Oxford Biomedica PLC.
• Voyager Therapeutics Inc.
• Human Stem Cells Institute
• Dimension Therapeutics, Inc.
• Bristol-Myers Squibb Company
• Sanofi
• F. Hoffmann-La Roche Ltd
• bluebird bio, Inc.
• Novartis AG
• uniQure NV.

Report Scope:

In this report, the Global Gene Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Therapy Market, By Vector Type:

• Viral Vector
• Non-Viral Vector

Gene Therapy Market, By Delivery Method:

• In-Vivo
• Ex-Vivo

Gene Therapy Market, By Indication:

• Rare Diseases
• Cancer
• Neurological Diseases
• Others

Gene Therapy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Therapy Market.

Available Customizations:

Global Gene Therapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

4.1 Ongoing Clinical Trials

4.2 Completed Clinical Trials

4.3 Terminated Clinical Trials

4.4 Breakdown of Pipeline, By Development Phase

4.5 Breakdown of Pipeline, By Status

4.6 Breakdown of Pipeline, By Study Type

4.7 Breakdown of Pipeline, By Region

4.8 Clinical Trials Heat Map

5. Voice of Customer

6. Global Gene Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 6.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 6.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 6.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
  • 6.2.5. By Company (2024)
• 6.3. Market Map
• 6.3.1 By Vector Type
• 6.3.2 By Delivery Method
• 6.3.3 By Indication
• 6.3.4 By Region

7. North America Gene Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 7.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 7.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Gene Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Vector Type
      • 7.3.1.2.2. By Delivery Method
      • 7.3.1.2.3. By Indication
  • 7.3.2. Canada Gene Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Vector Type
      • 7.3.2.2.2. By Delivery Method
      • 7.3.2.2.3. By Indication
  • 7.3.3. Mexico Gene Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Vector Type
      • 7.3.3.2.2. By Delivery Method
      • 7.3.3.2.3. By Indication

8. Europe Gene Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 8.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 8.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 8.2.4. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Gene Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Vector Type
      • 8.3.1.2.2. By Delivery Method
      • 8.3.1.2.3. By Indication
  • 8.3.2. Germany Gene Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Vector Type
      • 8.3.2.2.2. By Delivery Method
      • 8.3.2.2.3. By Indication
  • 8.3.3. United Kingdom Gene Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Vector Type
      • 8.3.3.2.2. By Delivery Method
      • 8.3.3.2.3. By Indication
  • 8.3.4. Italy Gene Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Vector Type
      • 8.3.4.2.2. By Delivery Method
      • 8.3.4.2.3. By Indication
  • 8.3.5. Spain Gene Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Vector Type
      • 8.3.5.2.2. By Delivery Method
      • 8.3.5.2.3. By Indication

9. Asia-Pacific Gene Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 9.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 9.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 9.2.4. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Gene Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Vector Type
      • 9.3.1.2.2. By Delivery Method
      • 9.3.1.2.3. By Indication
  • 9.3.2. India Gene Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Vector Type
      • 9.3.2.2.2. By Delivery Method
      • 9.3.2.2.3. By Indication
  • 9.3.3. Japan Gene Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Vector Type
      • 9.3.3.2.2. By Delivery Method
      • 9.3.3.2.3. By Indication
  • 9.3.4. South Korea Gene Therapy Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Vector Type
      • 9.3.4.2.2. By Delivery Method
      • 9.3.4.2.3. By Indication
  • 9.3.5. Australia Gene Therapy Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Vector Type
      • 9.3.5.2.2. By Delivery Method
      • 9.3.5.2.3. By Indication

10. South America Gene Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 10.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 10.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Gene Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Vector Type
      • 10.3.1.2.2. By Delivery Method
      • 10.3.1.2.3. By Indication
  • 10.3.2. Argentina Gene Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Vector Type
      • 10.3.2.2.2. By Delivery Method
      • 10.3.2.2.3. By Indication
  • 10.3.3. Colombia Gene Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Vector Type
      • 10.3.3.2.2. By Delivery Method
      • 10.3.3.2.3. By Indication

11. Middle East and Africa Gene Therapy Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Vector Type (Viral Vector, Non-Viral Vector)
  • 11.2.2. By Delivery Method (In-Vivo, Ex-Vivo)
  • 11.2.3. By Indication (Rare Diseases, Cancer, Neurological Diseases, Others)
  • 11.2.4. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Gene Therapy Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Vector Type
      • 11.3.1.2.2. By Delivery Method
      • 11.3.1.2.3. By Indication
  • 11.3.2. Saudi Arabia Gene Therapy Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Vector Type
      • 11.3.2.2.2. By Delivery Method
      • 11.3.2.2.3. By Indication
  • 11.3.3. UAE Gene Therapy Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Vector Type
      • 11.3.3.2.2. By Delivery Method
      • 11.3.3.2.3. By Indication

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Development
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Global Gene Therapy Market: SWOT Analysis

15. Funding Analysis

16. Porter's Five Forces Analysis

• 16.1. Competition in the Industry
• 16.2. Potential of New Entrants
• 16.3. Power of Suppliers
• 16.4. Power of Customers
• 16.5. Threat of Substitute Products

17. Competitive Landscape

• 17.1. REGENXBIO Inc.
  • 17.1.1. Business Overview
  • 17.1.2. Company Snapshot
  • 17.1.3. Products & Services
  • 17.1.4. Financials (As Reported)
  • 17.1.5. Recent Developments
  • 17.1.6. Key Personnel Details
  • 17.1.7. SWOT Analysis
• 17.2. Oxford Biomedica PLC.
• 17.3. Voyager Therapeutics Inc.
• 17.4. Human Stem Cells Institute
• 17.5. Dimension Therapeutics, Inc.
• 17.6. Bristol-Myers Squibb Company
• 17.7. Sanofi
• 17.8. F. Hoffmann-La Roche ltd.
• 17.9. bluebird bio, Inc.
• 17.10. Novartis AG
• 17.11. Uniqure N.V.

16. Strategic Recommendations

17. About Us & Disclaimer